Similarly, BiTE therapies designed to link T-cell CD3 with MM-specific receptors besides CD38, such as BCMA, CD19, G-protein–coupled receptor family C group 5 member D (GPRC5D), and the Fc receptor-like protein 5 (FcRH5) have shown good efficacy in preclinical studies and are now being investigated in clinical trials (reviewed by Abramson [102]). This evidence concerns the gene CD19 and Miyoshi myopathy.